Novartis Ag ADR (NVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2018 | 12-2017 | 09-2017 | 06-2017 | 03-2017 | |
| Sales | 12,929,000 | 13,164,000 | 12,692,000 | 12,494,000 | 11,785,000 |
| Cost of Goods | 4,355,000 | 4,489,000 | 4,323,000 | 4,258,000 | 4,105,000 |
| Gross Profit | 8,574,000 | 8,675,000 | 8,369,000 | 8,236,000 | 7,680,000 |
| Operating Expenses | 6,127,000 | 6,605,000 | 6,012,000 | 5,956,000 | 5,758,000 |
| Operating Income | 2,447,000 | 2,070,000 | 2,357,000 | 2,280,000 | 1,922,000 |
| Interest Expense | 224,000 | 208,000 | 197,000 | 192,000 | 180,000 |
| Other Income | 186,000 | 439,000 | 276,000 | 227,000 | 205,000 |
| Pre-tax Income | 2,409,000 | 2,301,000 | 2,436,000 | 2,315,000 | 1,947,000 |
| Income Tax | 381,000 | 325,000 | 353,000 | 336,000 | 282,000 |
| Net Income Continuous | 2,028,000 | 1,976,000 | 2,083,000 | 1,979,000 | 1,665,000 |
| Minority Interests | 3,000 | N/A | 2,000 | -1,000 | -1,000 |
| Net Income | $2,025,000 | $1,976,000 | $2,081,000 | $1,980,000 | $1,666,000 |
| EPS Basic Total Ops | 0.87 | -1.70 | 0.89 | 0.84 | 0.70 |
| EPS Basic Continuous Ops | 0.87 | -1.70 | 0.89 | 0.84 | 0.70 |
| EPS Diluted Total Ops | 0.86 | -1.68 | 0.88 | 0.83 | 0.70 |
| EPS Diluted Continuous Ops | 0.86 | -1.67 | 0.88 | 0.83 | 0.70 |
| EBITDA(a) | $2,447,000 | $3,538,000 | $2,357,000 | $2,280,000 | $1,922,000 |